Our analysis revealed a marked upregulation of NOD2 transcript levels in GBM specimens (n = 153) relative to normal brain parenchyma (n = 5), indicating aberrant NOD2 activation in malignant gliomas (Figure 1A). This evidence concerns the gene NOD2 and glioblastoma.